Truist upgraded Pacira (PCRX) to Hold from Sell with a $25 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira Pharmaceuticals Announces Leadership Changes and Plan Amendment
- Pacira appoints Teehan as CCO, Corbett as CBO
- Shareholders that lost money on Pacira BioSciences, Inc.(PCRX) should contact Levi & Korsinsky LLP about pending Class Action – PCRX
- Pacira price target raised to $30 from $22 at Needham
- Pacira sees FY24 revenue $701M, consensus $695.18M